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Introduction
Disorders of mineral metabolism such as hypercalcaemia, hyperphosphataemia and secondary hyperparathyroidism are common among patients suffering from end-stage renal disease (ESRD) . Several observational studies have demonstrated a strong association of abnormalities in mineral metabolism and all-cause mortality. [1] [2] [3] [4] [5] In addition, growing evidence suggests that altered mineral metabolism contributes to the development of cardiovascular disease (CVD) and cardiovascular mortality. [2] [3] [4] 6 Cardiovascular mortality is 10 to 20 times higher in dialysis patients than in the age-and sexmatched general population. 7, 8 Because CVD causes about 50 percent of mortality in dialysis patients 9 and has been proven to be related to disturbances in mineral metabolism, management of mineral metabolism has become an issue of major importance. In 2003, the Kidney Disease Outcomes Quality Initiative (K/DOQI) of the National Kidney Foundation introduced a guideline for bone metabolism and disease in chronic kidney disease (CKD) to assist nephrologists in developing an integrated approach to the diagnosis and management of mineral metabolism disorders. 10 This guideline recommends tight control of serum calcium, phosphorus, calcium-phosphorus (Ca x P) product and intact parathyroid hormone (iPTH) concentrations. This guideline was predominantly based on studies in haemodialysis (HD) patients.
Previous cross-sectional studies of prevalent HD patients found that elevated phosphorus, Ca x P product and iPTH levels increase cardiovascular mortality risk. 1, 3, 4, 6 In addition, Block et al. 2 observed recently that hyperphosphataemia and hyperparathyroidism were significantly associated with cardiovascular hospital admission rates in prevalent HD patients in the US. These studies so far examined only the effects of disordered mineral metabolism on the development of cardiovascular morbidity and mortality in HD patients. However, in clinical practice the K/DOQI guideline is applied to peritoneal dialysis (PD) patients as well, and evidence is needed to validate the implementation of the guideline in this group of patients. Since the associations between disordered mineral metabolism, according to the K/DOQI guideline, and cardiovascular morbidity and mortality have never been studied before in PD patients, the objective of our study was to evaluate these associations in incident PD patients in comparison with HD patients.
Subjects and Methods

Subjects
In the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD), a large prospective multicentre cohort study, ESRD patients are followed from the initiation of dialysis until transplantation or death. In 38 out of the 50 dialysis units in the Netherlands, all new ESRD patients were consecutively invited to participate in the study. To be eligible for the study, patients had to be 18 years or older and dialysis had to be their first renal replacement therapy. The study was approved by all local medical ethics committees and all patients gave informed consent before inclusion. Patients were followed until transplantation, mortality, or 1 January 2005.
For this analysis, we selected patients who had started on chronic PD or HD treatment in the period between January 1997 and July 2004. Patients who had measurements of plasma calcium, phosphorus, iPTH and albumin concentrations available at three months after the start of dialysis (baseline) were included. Since most of our patients had started on dialysis treatment before the publication of the K/DOQI guidelines (2003), nephrologists probably were not aiming for these targets. The resulting large variation in plasma concentrations enabled us to study the effects of K/DOQI-targets on outcome.
A total of 229 patients (14%) switched from treatment modality during the study. There were 174 PD patients who switched to HD therapy and the median time until the first switch of therapy was 620 days for these patients. Besides, there were 55 HD patients who switched to PD treatment during the study and the median time until modality switch was 540 days in this group of patients.
Data collection
Data on demography, primary kidney disease and comorbidity were collected zero to four weeks before the initiation of dialysis treatment. During follow-up, data on residual renal function, biochemistry and dialysis characteristics were collected at fixed times, i.e. at three and six months after the start of dialysis and subsequently at six-month intervals.
Reasons for hospital admission were classified as CVD in case of a diagnosis of myocardial infarction, cerebrovascular accident, coronary artery disease, cardiac failure, peripheral vascular disease, hypertension, or other cardiac disease. Primary kidney disease and causes of death were classified according to the codes of the European Renal Association-Dialysis and Transplantation Association (ERA-EDTA). Cardiovascular mortality was defined as any death attributed to myocardial ischaemia and infarction, cardiac failure, cardiac arrest (cause unknown), cerebrovascular accident, fluid overload, hyper-and hypokalaemia, haemorrhage from a ruptured aneurism or mesenteric infarction. Whenever the cause of death was uncertain or could not be determined, we classified it as cardiovascular because these patients in general died acutely. All other causes of death were classified as non-cardiovascular.
Patients were classified as having no, intermediate or severe comorbidity based on the number of comorbid conditions according to Davies' comorbidity index. 11 The nutritional status was scored on the standardized seven-point scale of the Subjective Global Assessment (SGA) which is based on the clinical judgment of the dialysis nurse. We defined malnourishment as an SGA score of five or lower. Residual renal function was expressed as residual glomerular filtration rate (rGFR), calculated as the mean of creatinine and urea clearance adjusted for body surface area (mL/min/1.73 m 2 ). Dialysis dose, the Kt/V urea per week, was calculated as dialysis urea clearance, divided by urea distribution volume (V) according to Watson et al. 12 For HD patients dialysis urea clearance was calculated using a second-generation Daugirdas formula, and for PD patients Kt/V urea was calculated from a 24-hour dialysate collection. 13 Laboratory variables were evaluated in reference to the targets advised in the K/DOQI guideline for bone metabolism and disease in CKD. This guideline recommends serum concentrations of corrected calcium between 8.4 and 9.5 mg/dl (2.10 and 2.37 mmol/l) and serum phosphorus concentrations between 3.5 and 5.5 mg/dl (1.13 and 1.78 mmol/l). Ca x P product concentrations should be <55 mg 2 /dl 2 (<4.4 mmol 2 /l 2 ) and iPTH concentrations should range from 150 to 300 pg/ml (15.8 to 31.6 pmol/l). Plasma calcium, phosphorus and albumin were measured by standard laboratory techniques in the different centres. Plasma calcium concentrations (mg/dl) were corrected for albumin concentration (g/dl) using the formula recommended by K/DOQI and generally applied in clinical practice [corrected calcium = calcium + 0.8 * (4 -albumin)]. 10 The Ca x P product in mg 2 /dl 2 was calculated by multiplying the corrected calcium concentration by the phosphorus concentration, both in mg/dl. Measurements of iPTH were performed by various first-generation immunometric iPTHassays depending on the different participating centres.
Statistical analysis
Patients were classified as HD or PD based on the treatment modality reported three months after the start of dialysis. To explore the differences between PD and HD patients we used standard descriptive statistics. We used a time-dependent Cox proportional hazards model for recurrent events to examine the relative risk of CVD-related hospital admission. To correct for the dependency between repetitive hospitalisations within the same patient, we added a frailty term to the statistical model. 14 The underlying logic of frailty models is that some patients are intrinsically more or less prone to develop CVD. Hazard ratios (HRs) for cardiovascular and non-cardiovascular mortality were calculated using time-dependent Cox proportional hazards regression models. In all time-dependent analyses the most recently measured plasma concentrations were used to predict effects on outcome in the subsequent period of six months. The analyses were stratified for treatment modality (PD or HD) and plasma concentrations were categorised in categories below, on, or above the K/DOQI targets. Patients with plasma concentrations that were either too low or too high were compared with patients who met the target (reference category). Adjustments were made for a number of possible confounding effects selected from the available literature. These included age, Davies' comorbidity score, primary kidney disease and SGA as recorded at baseline, and albumin level, Kt/V urea and haemoglobin level as time-dependent variables. Supplementary adjustments for laboratory parameters related to mineral metabolism were made for phosphorus and iPTH in analyses on the effects of calcium. We made similar additional adjustments for calcium and iPTH in analyses of phosphorus, for iPTH in analyses of Ca x P product, and for calcium and phosphorus in analyses of iPTH. All statistical analyses were performed using SAS statistical software version 9.1 (SAS Institute, Cary, NC), except for the frailty analysis, which was performed using the S-plus statistical software version 6.0.
Results
Description
Of the 1753 eligible patients, 1629 met the inclusion criteria. We had to exclude 124 patients due to missing plasma calcium, phosphorus, iPTH, or albumin levels at baseline. Compared with the included patients, the excluded patients more often had renal vascular disease, while diabetes mellitus and glomerulonephritis were less frequent causes of primary kidney disease. Other baseline characteristics of these patients did not differ from the included patients. The proportion of patients that died during the study period was higher among the excluded patients compared with the included patients (48% versus 36%, P =0.007).
Characteristics of the 1629 included patients three months after the start of dialysis are summarised in Table 1 . When compared with HD patients, PD patients were significantly younger, differed in the causes of primary kidney disease, had a higher rGFR, higher plasma calcium concentrations and lower phosphorus and Ca x P product concentrations. The proportion of HD patients with a moderate or high comorbidity score and with malnutrition were larger compared with PD patients. Three months after the initiation of dialysis, the majority of patients had plasma calcium concentrations exceeding the target range advised by K/DOQI. In PD patients, 29% had plasma calcium levels within the target range for calcium, while 40% of the HD patients met the guideline for calcium (P <0.001). Conversely, 50% of the PD patients met the phosphorustarget, whereas only 39% of the HD patients (P <0.001) had plasma phosphorus concentrations within the target range. In both patient groups, most of the remaining patients had higher plasma phosphorus levels than advised. The Ca x P product target was reached by 58% of the PD and 54% of the HD patients. More than half of the patients had plasma iPTH concentrations below the proposed target range, and 22% of the PD and 21% of the HD patients met the iPTH target. Percentages of patients with plasma concentrations below, on or above the targets are depicted in Figure 1 .
Hospital admissions
The maximal follow-up time was 7.8 years (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) . Median follow-up time was 29 months (2.4 years) in the PD group and 28 months (2.3 years) in the HD group. During the study period, 272 PD and 609 HD patients were hospitalised at least once. Hospital admissions related to the start of dialysis were not included in this count. In Table 2 , the cardiovascular reasons for hospital admission in PD and HD patients are listed. a N indicates the number of patients that were hospitalised. The numbers of hospitalised patients add up to more than the total number, because patients could have more than one CVD-related hospitalisation during follow-up. The number of hospitalisations indicates the total number of hospital admissions for each diagnosis. Hospital admissions related to initiation of dialysis treatment were excluded.
CVD was the reason for hospitalisation in 102 PD patients and in 271 HD patients. In total, 69 PD patients were hospitalised just one time due to a cardiovascular reason, 23 patients had two CVD-related hospitalisations and 33 PD patients had three or more hospitalisations. In HD patients these numbers were 165, 69, and 37, respectively. The most frequent noncardiovascular causes of hospitalisation were shunt or catheter problems and infections. The median duration of the first CVD-related hospital admission was eight days in PD patients and seven days in HD patients. In the adjusted analyses (Table 3) , we found a significantly increased risk of CVD-related hospitalisation of 4.3 (95% CI: 1.7 to 10.9) in PD patients with plasma calcium concentrations below the recommended target. In HD patients with elevated plasma calcium levels, we observed a significantly increased HR of 1.4. Plasma phosphorus, Ca x P product and iPTH concentrations below or above the K/DOQI targets did not alter cardiovascular morbidity risk.
Mortality Two-year patient survival was 86% in PD and 74% in HD patients. In total, 146 PD and 444 HD patients died during the study period. The proportion that died from CVD was higher in PD patients (52%) than in HD patients (45%, P =0.07). Other common causes of mortality were infections, malignant disease and refusal of further treatment by the patient or ceasing of the dialysis treatment for any other reason. The causes of death are listed in Table 4 . In the unadjusted analyses we observed only a significantly increased cardiovascular mortality risk (HR: 1.4; 95% CI: 1.0 to 1.9) in PD patients with elevated plasma calcium concentrations. No effects of plasma phosphorus, Ca x P product or iPTH concentrations outside the K/DOQI target ranges were found (data not shown). After adjusting for predefined confounders, we observed a significantly increased cardiovascular mortality risk of 2.4 for phosphorus and of 2.2 for Ca x P product concentrations above the K/DOQI thresholds in PD patients. Similarly, cardiovascular mortality in HD patients was increased for elevated plasma phosphorus (HR: 1.5) and for plasma Ca x P product (HR: 1.5) concentrations. We did not observe any effect on cardiovascular mortality of plasma calcium or iPTH concentrations beyond the K/DOQI targets. HRs for cardiovascular mortality are shown in Tables 5 and 6 . In addition, we analysed the relative risk of non-cardiovascular mortality (Tables 5 and 6 ). We found that HD patients with plasma Ca x P product concentrations above the target had a 40% increased non-cardiovascular mortality risk. We did not find an effect on association of non-cardiovascular mortality with plasma concentrations below or above the prescribed targets in PD patients. 0.52 1.9 (0.8-4.6) 0.16 K/DOQI guideline ranges: serum calcium 8.4-9.5 mg/dl, serum phosphorus 3.5-5.5 mg/dl, Ca x P product <55 mg 2 /dl 2 , iPTH 150-300 pg/ml. a Multivariate model contained: calcium, phosphorus, iPTH, age, comorbidity, primary kidney disease, nutritional status (SGA), albumin, Kt/Vurea per week, and haemoglobin. Table 6 . Time-dependent adjusted a hazard ratios (95% CI) for cardiovascular and noncardiovascular mortality in HD patients. .40 K/DOQI guideline ranges: serum calcium 8.4-9.5 mg/dl, serum phosphorus 3.5-5.5 mg/dl, Ca x P product <55 mg 2 /dl 2 , iPTH 150-300 pg/ml. a Multivariate model contained: calcium, phosphorus, iPTH, age, comorbidity, primary kidney disease, nutritional status (SGA), albumin, Kt/Vurea per week, and haemoglobin.
In addition, we examined whether receiving phosphate binders was protective or not against cardiovascular mortality by adding the use of phosphate binders as a variable to our timedependent model. This analysis did not alter the conclusions from the initial model.
As 19% of the patients switched from treatment modality during the study period, we also performed an analysis in which we censored the observation time of patients at the moment that they switched dialysis modality. This additional analysis did not affect our results in any way.
Discussion
In the current study, we showed that disordered mineral metabolism has a limited effect on the risk of hospital admission with a cardiovascular reason. Only in HD patients with plasma calcium concentrations above the K/DOQI target did we observe an increased relative risk of CVD-related hospitalisation. Associations with cardiovascular mortality were more pronounced; plasma phosphorus and Ca x P product concentrations above the K/DOQI thresholds significantly increase cardiovascular mortality in both PD and HD patients. No significant association of abnormal plasma iPTH concentration with cardiovascular morbidity or mortality was found. These findings indicate that associations of plasma concentrations outside the target ranges advised in the K/DOQI guideline with cardiovascular mortality are similar in both patient groups.
Our study has some limitations. First, when the cause of death was uncertain or not determined, we classified it as cardiac arrest and thus as cardiovascular mortality because in these cases the patients died acutely. As a consequence, the proportion of cardiovascular causes of death may be slightly overestimated. However, this proportion is in concordance with the international literature 9 , and when we performed an analysis in which an uncertain or undetermined cause of death was classified as non-cardiovascular, this had only a minor influence on our results. We may have underestimated the proportion of CVD-related hospital admissions, since we focused on primary diagnoses of hospitalisations and secondary diagnoses or events during hospitalisation were not taken into account. Finally, data on the type of prescribed phosphate binders and the use of vitamin D analogues were not available. About 90% of both PD and HD patients used phosphate binders at baseline. Over time, this proportion remained stable in the PD group and increased to a maximum of 97% in the fourth year after start of dialysis in the HD group. The proportion of HD patients that used phosphate binders was over time somewhat higher than the proportion of PD patients, although this difference was only significant in the second year after start of dialysis. During the greater part of the study period non-calcium containing phosphate binders were not yet available in The Netherlands during the greater part of the study period and we assume that the majority of patients was treated with calcium acetate or calcium carbonate. In addition, some patients, especially those with severe hyperphosphataemia, might have been treated with aluminium-containing phosphate binders. The elevated plasma calcium concentrations that we observed could have been caused by the use of calcium-based phosphate binders and vitamin D analogues. As a result of the relatively high calcium levels, iPTH concentrations were probably suppressed and, in addition, PTH-release could be directly restrained by vitamin D analogues. 15, 16 On the other hand, HD patients receiving some form of injectable active vitamin D have recently been shown to be at survival advantage compared with patients who did not, and this survival benefit was present at all levels of serum calcium, phosphorus, or PTH. 17 A recent study has indicated that therapeutic interventions associated with excessive lowering of parathyroid activity like parathyroidectomy or a high calcium load favour low bone turnover and adynamic bone disease which could influence the development and progression of arterial calcifications. 18 We did not observe a relationship between iPTH and cardiovascular morbidity or mortality. Furthermore, only 67 patients (4.1%) underwent subtotal or total parathyroidectomy during the study period.
In a recent analysis of the United States Renal Data System (USRDS) cohort, Block et al. 2 observed that hyperphosphataemia and hyperparathyroidism were significantly associated with cardiovascular hospitalisations in prevalent HD patients. However, in our study we found that in incident HD patients, CVD-related hospital admissions were associated with elevated calcium concentrations and we could not detect any significant effects of elevated plasma phosphorus, Ca x P product or iPTH levels. These discrepancies could be due to differences in methodology. The cross-sectional study in prevalent patients of Block et al. used higher thresholds whereas the present study focused on target limits as recommended by K/DOQI and the sample size of this American study was substantially larger than of our study. 2 So far, no one has studied these effects in PD patients.
In PD patients we also observed a significant association of cardiovascular morbidity with plasma calcium concentrations below 8.4 mg/dl (2.10 mmol/l, HR: 4.3). We cannot explain this finding, but it should be kept in mind that only 48 out of 586 PD patients (8%) had at least once during follow-up, a plasma calcium concentration below the K/DOQI target range. A total of six CVD-related hospitalisations in four of these patients accounted for the observed association, which indicates that this association might be based on coincidence.
Several studies have been performed to determine the association between mineral metabolism and cardiovascular mortality. [2] [3] [4] 6 In a cohort of 17236 HD patients participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS), Young et al. 4 found increased relative risks of cardiovascular death in HD patients with elevated serum concentrations of phosphorus, Ca x P product and PTH. Similarly, Ganesh et al. 3 observed an increase of 41% of cardiovascular mortality risk in prevalent HD patients from the USRDS study who had serum phosphorus levels above 6.5 mg/dl (2.1 mmol/l) compared with patients with serum levels between 2.4 and 6.5 mg/dl (0.8-2.1 mmol/l). The mortality risks that we observed in HD patients were similar to the findings in those previous studies. We are not aware of any previous studies in PD patients.
Associations of abnormal phosphorus and Ca x P product concentrations with cardiovascular mortality were similar to those with non-cardiovascular mortality in HD patients. In PD patients, however, no associations with non-cardiovascular mortality could be detected. These results indicate that the association between disturbed mineral metabolism and cardiovascular mortality risk is similar for both treatment modalities, while the risk of non-cardiovascular mortality was only related to abnormalities in mineral metabolism in HD patients.
Several mechanisms may be involved in the increased cardiovascular morbidity and mortality associated with disordered mineral metabolism. Vascular and tissue calcification is increasingly recognised as a frequent complication in ESRD. 18 Moreover, cardiac valve calcification is a strong predictor for all-cause and cardiovascular mortality in long-term dialysis patients. 19 Growing evidence indicates that uraemic vascular calcification is an active and regulated cellmediated process similar to osteogenesis in bone, rather than a passive precipitation of calcium and phosphorus. In this process, vascular smooth muscle cells (VSMCs) transform into osteoblast-like cells which are capable of calcification in vitro. 20 Several stimuli such as oxidised low-density lipoprotein, high concentrations of PTH and vitamin D derivates have been shown to induce the transformation of VSMCs. In addition, increasing evidence implies that elevated plasma phosphorus and Ca x P product concentrations could be important stimuli for excess vascular calcification in uraemic patients 21 , which is confirmed by the findings of our current study. A lack of protective factors, such as the calcification-inhibiting glycoprotein fetuin-A (α2-Heremans-Schmid glycoprotein), may also contribute to the pathogenesis of uraemic vascular calcifications. 22, 23 In conclusion, associations of disturbances in mineral metabolism with cardiovascular mortality are more pronounced than effects on associations with CVD-related hospitalisations. Only in HD patients with plasma calcium concentrations above the K/DOQI threshold is the relative risk of CVD-related hospital admission increased. Cardiovascular mortality risk is increased in PD and in HD patients with elevated plasma phosphorus and Ca x P product concentrations. Therefore, it seems appropriate to adopt the current guideline for PD patients.
